SP16 Trial Aims to Prevent Acute Kidney Injury in CKD Patients Undergoing Cardiac Surgery
A clinical trial is underway to evaluate the efficacy and safety of SP16 in preventing acute kidney injury in patients with chronic kidney disease undergoing cardiac surgery.
Phase III
patients with chronic kidney disease
Status
Active
Sponsor
Serpin Pharma, LLC
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Positive trial results could enhance Serpin Pharma's portfolio and open avenues for further development in related indications, impacting strategic partnerships and investment.
Why it matters
The ongoing clinical trial of SP16 is significant as it targets a critical unmet need in preventing acute kidney injury during cardiac surgery for patients with chronic kidney disease. Successful outcomes could enhance Serpin Pharma's positioning in nephrology and lead to new therapeutic avenues.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial enrollment progress, interim results, and any announcements regarding efficacy outcomes.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.